Exploring New Endpoints for Patients With Heart Failure With Preserved Ejection Fraction
Population
Patients with heart failure with preserved ejection fraction (HFpEF)
Design
Review
Authors
Discussion
Loading...
Member takes
Implication
May guide HFpEF trial design toward patient-centric endpoints; leaves open effects on future approvals.
Structured PICO
P
Population
Patients with heart failure with preserved ejection fraction (HFpEF)
Highlights the consensus from an FDA-facilitated meeting on the critical need to incorporate patient-centric endpoints like functional capacity and quality of life in HFpEF drug development.
Cite This Study
Butler et al. (2016) studied this question.